EDMONTON, July 18 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced the granting of 400,000 stock options subject to approval by the TSX-Venture Exchange. Mr. Shawn McMillan, an officer of Ceapro, was awarded 150,000 options and Consultants were awarded 250,000. The exercise price is $0.28, the closing price of Ceapro's shares on the date of the grant. The options were awarded in accordance with the Stock Option Plan approved by Shareholders on June 1, 2005 and by the TSX-Venture Exchange on July 6, 2005. "We are pleased to use our Stock Option Plan to recognize the significant contributions made by these individuals to advance Ceapro's markets, especially in the field of our CeaProve(TM) diabetes screening, diagnostic, and management technology. Stock options are also critical in retaining key employees and providing incentive to increase their proprietary interest in the Company." About Ceapro Ceapro Inc., an innovation-driven biotechnology company, develops and commercializes organic products for medical, cosmetic, and animal health industries using proprietary technology and natural, renewable resources. Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing Companies for 2004 and 2005 and is one of Profit Magazine's Next 100 Companies. Ceapro is also the recipient of the ASTech Award for Outstanding Commercial Achievement for companies with annual sales of less than $25 million. Ceapro's shares trade on the TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, log on to our website at www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.28. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. %SEDAR: 00010110E
Ceapro Announces Granting of Stock Options
Earlier from Ceapro
- Ceapro announces officer appointment
- Ceapro Announces Highlights of Today's Annual General and Special Meeting
- Ceapro to present at BioFinance conference
- Ceapro announces 2004 financial results
- Ceapro receives further investment from AVAC Ltd.
Later from Ceapro
- Ceapro announces 2005 second quarter financial results
- Ceapro announces adoption of CeaProve(TM) in global Glycemic Index study
- Ceapro to present CeaProve(TM) at Canadian Diabetes Association conference
- Ceapro announces 2005 third quarter financial results
- Ceapro successfully closes $1.3 million financing
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro